Login Register Cart 0
Systematic Review Article

2型糖尿病患者服用蝶香素对心脏代谢的影响:临床试验的系统回顾和荟萃分析

卷 28, 期 4, 2021

发表于: 28 July, 2020

页: [840 - 852] 页: 13

弟呕挨: 10.2174/0929867327666200728134755

价格: $65

摘要

背景：本研究对临床试验进行了系统回顾和荟萃分析，以评估服用胰岛素对2型糖尿病(T2DM)患者心脏代谢的影响。 方法：检索PubMed、EMBASE、Scopus、Web of Science、谷歌Scholar和Cochra ne Central Register of Controlled Trials等电子数据库，检索起始至2019年7月31日。采用Cochran ''s Q检验和I-square (I2)统计量评估统计异质性。数据采用随机效应模型和加权平均差(WMD)进行汇总。 结果：从1733篇引用中，有7个临床试验符合纳入和荟萃分析的条件。血红蛋白A1c (HbA1c)显著降低(WMD -0.73;95%CI -1.25 ~ -0.21;P = 0.006;I2= 72.2%)和体重指数(BMI) (WMD -0.55;95%CI -1.03 ~ -0.07;P = 0.026;I2= 9.5%)被识别。然而，对空腹血糖(FBS)无显著影响(WMD -9.00;95%CI -22.57 ~ 4.57;P = 0.194;I2= 60.5%)，胰岛素抵抗稳态模型评估(HOMA-IR) (WMD 0.39;95%CI -0.95 ~ 1.73;P = 0.569;I2= 2.2%)，体重(WMD - 0.54;95%CI -1.10 - 0.02;P= 0.059)、甘油三酯(WMD -0.56;95%CI -24.16 ~ 23.03;P = 0.963;I2= 0.0%)、总胆固醇(WMD -0.21;95%CI -12.19 - 11.78;P = 0.973;I2= 0.0%)、hdl -胆固醇(WMD -0.96;95%CI -2.85 ~ 0.93;P = 0.321;I2= 0.0%)， ldl -胆固醇水平(WMD -0.09;95%CI -8.43 ~ 8.25;P = 0.983;I2 = 37.8%)。 结论：服用双醋瑞因可降低HbA1c和BMI;然而，在胎牛血清、HOMA-IR、体重、甘油三酯、总胆固醇、高密度脂蛋白胆固醇或低密度脂蛋白胆固醇方面没有观察到影响的证据。

关键词: 双醋瑞因，糖尿病，心脏代谢，Meta分析，体重，甘油三酯

« Previous
[1]
Hamoudi, R.; Saheb Sharif-Askari, N.; Saheb Sharif-Askari, F.; Abusnana, S.; Aljaibeji, H.; Taneera, J.; Sulaiman, N. Prediabetes and diabetes prevalence and risk factors comparison between ethnic groups in the United Arab Emirates. Sci. Rep., 2019, 9(1), 17437.
[http://dx.doi.org/10.1038/s41598-019-53505-7] [PMID: 31767874]
[2]
IDF Diabetes Atlas, Brussels: International Diabetes Federation, 8th Edition; , 2017.
[3]
Lourenço, C.; Kelly, D.; Cantillon, J.; Cauchi, M.; Yon, M.A.; Bentley, L.; Cox, R.D.; Turner, C. Monitoring type 2 diabetes from volatile faecal metabolome in Cushing’s syndrome and single Afmid mouse models via a longitudinal study. Sci. Rep., 2019, 9(1), 18779.
[http://dx.doi.org/10.1038/s41598-019-55339-9] [PMID: 31827172]
[4]
Classification of diabetes mellitus. Geneva:; World Health Organization, 2019.
[5]
Saydah, S.H.; Siegel, K.R.; Imperatore, G.; Mercado, C.; Gregg, E.W. The cardiometabolic risk profile of young adults with diabetes in the US. Diabetes Care, 2019, 42(10), 1895-1902.
[http://dx.doi.org/10.2337/dc19-0707] [PMID: 31221678]
[6]
Louthrenoo, W.; Nilganuwong, S.; Nanagara, R.; Siripaitoon, B.; Collaud Basset, S. Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial. Clin. Rheumatol., 2019, 38(9), 2461-2471.
[http://dx.doi.org/10.1007/s10067-019-04587-1] [PMID: 31104217]
[7]
Malaguti, C.; Vilella, C.A.; Vieira, K.P.; Souza, G.H.; Hyslop, S. Zollner, Rde.L. Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in non-obese diabetic (NOD) mice. Int. Immunopharmacol., 2008, 8(6), 782-791.
[http://dx.doi.org/10.1016/j.intimp.2008.01.020] [PMID: 18442781]
[8]
Tres, G.S.; Fuchs, S.C.; Piovesan, F.; Koehler-Santos, P.; Pereira, F.D.S.; Camey, S.; Lisboa, H.K.; Moreira, L.B. Effect of diacerein on metabolic control and inflammatory markers in patients with type 2 diabetes using antidiabetic agents: a randomized controlled trial. J. Diabetes Res., 2018, 20184246521
[http://dx.doi.org/10.1155/2018/4246521] [PMID: 29805981]
[9]
Piovesan, F.; Tres, G.S.; Moreira, L.B.; Andrades, M.E.; Lisboa, H.K.; Fuchs, S.C. Effect of diacerein in renal function, metabolic control, and inflammatory markers in type 2 diabetic patients with nephropathy. PLoS One, 2013, 12(10)e0186554
[http://dx.doi.org/10.1371/journal.pone.0186554 ] [PMID: 29049415]
[10]
Piovesan, F.; Tres, G.S.; Moreira, L.B.; Andrades, M.E.; Lisboa, H.K.; Fuchs, S.C. Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: a randomized controlled trial. PLoS One, 2017, 12(10)e0186554
[http://dx.doi.org/10.1371/journal.pone.0186554] [PMID: 29049415]
[11]
Ramos-Zavala, M.G.; González-Ortiz, M.; Martínez-Abundis, E.; Robles-Cervantes, J.A.; González-López, R.; Santiago-Hernández, N.J. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care, 2011, 34(7), 1591-1594.
[http://dx.doi.org/10.2337/dc11-0357] [PMID: 21610123]
[12]
Cardoso, C.R.L.; Leite, N.C.; Carlos, F.O.; Loureiro, A.A.; Viegas, B.B.; Salles, G.F. Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Care, 2017, 40(10), 1356-1363.
[http://dx.doi.org/10.2337/dc17-0374] [PMID: 28818994]
[13]
Villar, M.M.; Martínez-Abundis, E.; Preciado-Márquez, R.O.; González-Ortiz, M. Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch. Endocrinol. Metab., 2017, 61(2), 188-192.
[http://dx.doi.org/10.1590/2359-3997000000242] [PMID: 28225996]
[14]
Guyatt, G.H.; Oxman, A.D.; Vist, G.E.; Kunz, R.; Falck-Ytter, Y.; Alonso-Coello, P.; Schünemann, H.J. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650), 924-926.
[http://dx.doi.org/10.1136/bmj.39489.470347.AD] [PMID: 18436948]
[15]
Joo, N-S.; Kim, S-M.; Kim, K-M.; Kim, C-W.; Kim, B-T.; Lee, D-J. Changes of body weight and inflammatory markers after 12-Week intervention trial: results of a double-blind, placebo-control pilot study. Random. Control. Trial, 2011, 52(2), 242-248.
[http://dx.doi.org/10.3349/ymj.2011.52.2.242] [PMID: 21319341]
[16]
Leite, N.C.; Viegas, B.B.; Villela-Nogueira, C.A.; Carlos, F.O.; Cardoso, C.R.L.; Salles, G.F. Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized, placebo-controlled trial. Diabetes Obes. Metab., 2019, 21(5), 1266-1270.
[http://dx.doi.org/10.1111/dom.13643] [PMID: 30687994]
[17]
Zhang, Q.; Zhou, J.; Wang, Y.; Chen, D. The effect and safety of diacerein in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Am. J. Clin. Exp. Immunol., 2017, 6(6), 97-106.
[PMID: 29348985]
[18]
Liu, S.; Hempe, J.M.; McCarter, R.J.; Li, S.; Fonseca, V.A. Association between inflammation and biological variation in hemoglobin A1c in U.S. nondiabetic adults. J. Clin. Endocrinol. Metab., 2015, 100(6), 2364-2371.
[http://dx.doi.org/10.1210/jc.2014-4454] [PMID: 25867810]
[19]
Wu, T.; Dorn, J.P.; Donahue, R.P.; Sempos, C.T.; Trevisan, M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the third national health and nutrition examination survey, 1988-1994. Am. J. Epidemiol., 2002, 155(1), 65-71.
[http://dx.doi.org/10.1093/aje/155.1.65] [PMID: 11772786]
[20]
Brown, C.O. A dose-ranging study of diacerein in patients with type 2 diabetes. In: Amer Diabetes Assoc 1701 N Beauregard ST, Alexandria, VA 22311-1717 USA, 2013.
[21]
Tobar, N.; Oliveira, A.G.; Guadagnini, D.; Bagarolli, R.A.; Rocha, G.Z.; Araújo, T.G.; Santos-Silva, J.C.; Zollner, R.L.; Boechat, L.H.; Carvalheira, J.B.; Prada, P.O.; Saad, M.J. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology, 2011, 152(11), 4080-4093.
[http://dx.doi.org/10.1210/en.2011-0249] [PMID: 21896669]

Rights & Permissions Print Cite
Article Metrics
19
1
© 2024 Bentham Science Publishers | Privacy Policy